Outcomes of poor responders following growth hormone co-treatment with IVF/ICSI mild stimulation protocol: a retrospective cohort study
- 369 Downloads
No research has studied the effect of GH co-treatment in mild stimulation protocol for poor responders. We therefore conducted this retrospective analysis to assess the outcome of IVF/ICSI cycles after the adjunct GH use to the mild stimulation protocol in poor responders.
132 poor responders who received mild stimulation protocol at Reproductive Medicine Center of Changzheng Hospital from January 2014 to December 2016 were included in this study. Good-quality embryo rate, clinical pregnancy rate, and live birth rate were compared between the GH group (n = 61) and control group (n = 71).
IVF good-quality embryo rate (68.1 versus 51.5%; P = 0.008*) and ICSI good-quality embryo rate (53.9 versus 36.7%; P = 0.045*) was significantly higher in the GH group. Though the clinical outcomes did not reach a statistically significant difference between the two groups due to the limited sample size, there was a trend of higher rate in GH group in the aspect of clinical pregnancy rate (52.4 versus 47.1%; P = 0.609) and live birth rate (35.7 versus 27.5%; P = 0.392).
The results suggested that the adjuvant GH treatment in mild stimulation protocol for poor responders could significantly improve good-quality embryo rate, and might therefore improve the clinical outcomes.
KeywordsPoor ovarian responder Mild stimulation protocol Growth hormone Good-quality embryo
We thank the patients for participating in this study.
WL conceived and designed the experiments. KC and WP performed the experiments and analyzed the data. KC and WL wrote the main manuscript. NS and QZ prepared the tables and revised the manuscript. All authors reviewed the manuscript.
This study was supported by the Science and Technology Commission of Shanghai Municipality [Grant Numbers 16DZ0500402, 1641963500].
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 22.Zhuang GL, Wong SX, Zhou CQ (1994) The effect of co-administration of low dosage growth hormone and gonadotropin for ovarian hyperstimulation in vitro fertilization and embryo transfer. Zhonghua Fu Chan Ke Za Zhi 29(8):471–474, 510Google Scholar
- 29.Weigert M, Krischker U, Pohl M, Poschalko G, Kindermann C, Feichtinger W (2002) Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study. Fertil Steril 78(1):34–39CrossRefPubMedGoogle Scholar
- 31.Hohmann FP, Macklon NS, Fauser BC (2003) A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 88(1):166–173CrossRefPubMedGoogle Scholar
- 36.Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A (2010) Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 1:Cd000099Google Scholar